Combination therapy of sorafenib and TACE for unresectable HCC: A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Liu, Lei ^a   Chen, Hui ^a   Wang, Mengmeng ^c   Zhao, Yan ^b   Cai, Guohong ^c   Qi, Xingshun ^a   Han, Guohong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ALOPECIA; BLOOD TOXICITY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER TOXICITY; META ANALYSIS; NAUSEA; OVERALL SURVIVAL; PATIENT SAFETY; RASH; REVIEW; SKIN EXFOLIATION; SKIN MANIFESTATION; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; DISEASE COURSE; LIVER NEOPLASMS; MULTIMODALITY CANCER THERAPY; SURVIVAL; TIME;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84906719099     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091124     Document Type: Review

References (33)

1. Faloppi L, Scartozzi M, Maccaroni E, Di Pietro Paolo M, Berardi R, et al. (2011) Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. Cancer treatment reviews 37: 169-177.
2. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. The New England journal of medicine 340: 745-750. (Pubitemid 29114292)
3. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA: a cancer journal for clinicians 55: 74-108. (Pubitemid 40372904)
4. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology (Baltimore, Md) 42: 1208-1236. (Pubitemid 43112690)
5. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. Journal of hepatology 35: 421-430. (Pubitemid 32844200)
6. Forner A, Reig ME, de Lope CR, Bruix J (2010) Current strategy for staging and treatment: the BCLC update and future prospects. Seminars in liver disease 30: 61-74.
7. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379: 1245-1255.
8. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X (2004) Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World journal of gastroenterology: WJG 10: 2878-2882. (Pubitemid 39303010)
9. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, et al. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular cancer therapeutics 7: 3129-3140.
10. Erhardt A, Kolligs FT, Dollinger MM, Schott E, Wege H, et al. (2009) Sorafenib plus TACE for the treatment of advanced hepatocellular carcinoma-final results of the SOCRATES trial. Hepatology (Baltimore, Md) 50: A1675.
11. Dufour JF, Hoppe H, Heim MH, Helbling B, Maurhofer O, et al. (2010) Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. The oncologist 15: 1198-1204.
12. Lee JH, Chung Y-H, Kim JA, Shin E-S, Lee D, et al. (2011) Single nucleotide polymorphism associated with tumor response to the combined therapy with trans-arterial chemoembolization and sorafenib in patients with hepatocellular carcinoma, abstract 518. The 46th Annual Meeting of the European Association for the Study of the Liver March 30 to April 3.
13. Cabrera R, Pannu DS, Caridi J, Firpi RJ, Soldevila-Pico C, et al. (2011) The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Alimentary pharmacology & therapeutics 34: 205-213.
14. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, et al. (2011) Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29: 3960-3967.
15. Chung YH, Han G, Yoon JH, Yang J, Wang J, et al. (2013) Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. International journal of cancer Journal international du cancer 132: 2448-2458.
16. Park JW, Koh YH, Kim HB, Kim HY, An S, et al. (2012) Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. Journal of hepatology 56: 1336-1342.
17. Qu XD, Chen CS, Wang JH, Yan ZP, Chen JM, et al. (2012) The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. BMC cancer 12: 263.
18. Sieghart W, Pinter M, Reisegger M, Muller C, Ba-Ssalamah A, et al. (2012) Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. European radiology 22: 1214-1223.
19. Zhao Y, Wang WJ, Guan S, Li HL, Xu RC, et al. (2013) Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 24: 1786-1792.
20. Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, et al. (2008) Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC cancer 8: 349.
21. Martin RC II, Keck G, Robbins K, Strnad B, Dubel G, et al. (2010) Evaluation of sorafenib in combination with doxorubicin-loaded DC bead as a combination treatment option for HCC. Abstract 216. ASCO Gastrointestinal Cancers Symposium January 22-24.
22. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, et al. (2011) Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. European journal of cancer (Oxford, England: 1990) 47: 2117-2127.
23. Lencioni R, Llovet JM, Han G, Tak W-Y, Yang J, et al. (2012) Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. J Clin Oncogene 30.
24. Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, et al. (2012) Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. The oncologist 17: 359-366.
25. Bai W, Wang YJ, Zhao Y, Qi XS, Yin ZX, et al. (2013) Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. Journal of digestive diseases 14: 181-190.
26. Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, et al. (2013) Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma. World journal of hepatology 5: 364-371.
27. Huang YH, Chen W, Li JP, Chen B, Yang JY (2013) Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Chinese medical journal 126: 385-386.
28. Martin R, Geller D, Espat J, Kooby D, Sellars M, et al. (2012) Safety and efficacy of trans arterial chemoembolization with drug-eluting beads in hepatocellular cancer: a systematic review. Hepato-gastroenterology 59: 255-260.
29. Higgins JPT, Green S (2009) Cochrane Hand-book for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. Available: www.cochrane-handboo.korg. The Cochrane Collaboration.
30. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, et al. (2011) Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer treatment reviews 37: 212-220.
31. Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, et al. (2013) Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver international: official journal of the International Association for the Study of the Liver 33: 327-337.
32. Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, et al. (2013) Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology 269: 603-611.
33. Weintraub JL, Salem R (2013) Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science. Journal of vascular and interventional radiology: JVIR 24: 1123-1134.